AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201510-05-2023
10-05-2023
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q4 FY23 Earning Conference Call07-05-2023
AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for issuance of Letter of Confirmation in lieu of Duplicate Share Certificate04-05-2023
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 202302-05-2023
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Recording of Conference Call02-05-2023
Aarti Drugs Results Earnings Call for Q4FY23
Conference Call with Aarti Drugs Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.02-05-2023
Aarti Drugs trades 5% higher on steady March quarter earnings
The company reported a 7 percent increase in revenue to Rs 743 crore compared to Rs 697 crore reported in the corresponding quarter of last fiscal while net profit increased marginally by 2 percent to Rs 56 crore.02-05-2023
AARTI DRUGS LTD. - 524348 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAARTI DRUGS LTD. 2CIN NO.L37060MH1984PLC055433 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 161.89 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Rushikesh Deole Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Adhish Patil Designation: Chief Financial Officer EmailId: [email protected] Date: 02/05/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.02-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Aarti Drugs Ltd.
Pharmaceutical company Aarti Drugs announced Q4FY23 & FY23 results: Q4FY23: Revenue stood at Rs 743.3 crore as against Rs 697.2 crore, a growth of 7% YoY EBITDA stood at Rs 94.4 crore as against Rs 89.0 crore YoY. EBITDA Margin (%) came in at 12.7% PAT stood at Rs 56.2 crore as against Rs 55.3 crore YoY. PAT Margin (%) stood at 7.6% Domestic revenue grew approximately by 13% while exports grew by around 7% YoY for Q4FY23 Q4FY23 revenue for formulation stood at Rs 56.8 crore as against Rs 66.6 crore Approximately 60% of the revenue came from exports during Q4FY23 FY23: Revenue stood at Rs 2,718.2 crore as against Rs 2,500.0 crore, a growth of 9% YoY EBITDA stood at Rs 307.8 crore as against Rs 340.8 crore YoY. EBITDA Margin (%) came in at 11.3% PAT stood at Rs 166.4 crore as against Rs 205.0 crore YoY. PAT Margin (%) stood at 6.1% Result PDF02-05-2023
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Q4FY23 Results presentation02-05-2023